Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibrosis

2015 ASCO Annual Meeting

29 May - 2 Jun 2015

Published: 30 May 2015

Views: 2216

Rating:

Save

Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA

Dr Mesa presents, at a press conference at ASCO 2015, findings from the PERSIST-1 study of patients with myelofibrosis that suggest that pacritinib is significantly more effective than best available therapy (BAT), which includes a range of off-label treatments.

Read the news article and watch the interview for more.

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Updates on lung cancer from WCLC and ESMO 2023

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Molecular oncology and translational medicine

Dr Gregg Fields - Florida Atlantic University, Florida, USA

Molecular oncology and translational medicine ( Dr Gregg Fields - Florida Atlantic University, Florida, USA )

Final OS analysis of ICARIA-MM: Isatuximab triplet shows continued survival...

Dr Paul Richardson - Dana Farber Cancer Institue, Boston, USA

Final OS analysis of ICARIA-MM: Isatuximab triplet shows continued survival benefit in R/R multiple myeloma ( Dr Paul Richardson - Dana Farber Cancer Institue, Boston, USA )

Treatment with tumour-infiltrating lymphocytes versus ipilimumab significantly...

Dr John B Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands

Treatment with tumour-infiltrating lymphocytes versus ipilimumab significantly improved PFS for advanced melanoma ( Dr John B Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands )

ASCO Direct Highlights 2022: lung cancer highlights

Dr Tom Stinchcombe - Duke Cancer Center, Durham, USA

ASCO Direct Highlights 2022: lung cancer highlights ( Dr Tom Stinchcombe - Duke Cancer Center, Durham, USA )

The advances in the management of patients with Hodgkin lymphoma and non...

Dr Eduardo Sotomayor - H. Lee Moffitt Cancer Center & Research Institute...

The advances in the management of patients with Hodgkin lymphoma and non-Hodgkin lymphoma ( Dr Eduardo Sotomayor - H. Lee Moffitt Cancer Center & Research Institute, Florida, USA )

ASCO 2022: Head and neck cancer highlights

Dr Mark Persky - NYU Langone’s Perlmutter Cancer Center, New York, USA

ASCO 2022: Head and neck cancer highlights ( Dr Mark Persky - NYU Langone’s Perlmutter Cancer Center, New York, USA )

More from ecancer